Thiocolchicoside

Summary

Thiocolchicoside (CHEMBL213907) is a phase-3 clinical-stage small molecule (ATC M03BX55); indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: M03BX55 (+1 more)
• Indications: 1 condition
• Clinical trials: 8
• Chemistry: 563.6 Da · C27H33NO10S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL213907
Name	Thiocolchicoside
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9915886
ATC	M03BX55, M03BX05
Molecular formula	C27H33NO10S
Molecular weight	563.6
InChIKey	LEQAKWQJCITZNK-AXHKHJLKSA-N

SMILES: CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O

IUPAC name: N-[(7S)-1,2-dimethoxy-10-methylsulfanyl-9-oxo-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide

Also known as: Coltramyl, Coltrax, Miorel, Musco-ril, NSC-147755, Thiocolchicoside, Tiocolchicosido, thiocolchicoside, SID56463708, SID144204021, THIOCOLCHICOSIDE

Patent coverage: 268 distinct patent families (889 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: GABA-A receptor; anion channel, Gamma-aminobutyric acid receptor subunit alpha-1.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
O09028	5.72	IC50	1900	nM	CHEMBL_ACT_1761267
O09028	5.47	IC50	3400	nM	CHEMBL_ACT_1761275
P62813	5.21	AC50	6200	nM	CHEMBL_ACT_25128638

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE4	4
PHASE2	2
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00272532	PHASE4	COMPLETED	EMINEM: Efficacy of Muscoril In NEck Myofascial Syndromes
NCT00917436	PHASE4	COMPLETED	Thiocolchicoside Injection and Capsule in Treatment of Acute Low Back Pain
NCT05529290	PHASE4	COMPLETED	Evaluation of the Efficacy of Different Drugs in the Treatment of the Pain in Patients With Temporomandibular Disorder
NCT07586072	PHASE4	COMPLETED	Non-Randomized Trial of Bruxism-Related TMD Treatments
NCT00679146	PHASE3	COMPLETED	Efficacy Safety of a Combination Thiocolchicoside+Ketoprofen Compared to Thiocolchicoside Twice a Day for 7 Days in Patients Suffering From Acute Non Specific Low Back Pain
NCT06261320	PHASE2	ACTIVE_NOT_RECRUITING	Mesotherapy Treatment of Irritable Bowel Syndrome
NCT04110119	PHASE2	COMPLETED	Effectiveness of Chiropractic Application for Acute Low Back Pain
NCT05261971	Not specified	COMPLETED	Evaluation of the Effects of Treatments Applied to Patients With Facial Myalgia on Occlusion Parameters

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).